Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

Explore the evolving landscape of myeloma treatment, focusing on maintenance therapies and patient experiences with ...

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...